Accumulating evidence has revealed that aberrant KEAP1-NRF2 signaling influences both cancer cells and the cancer-associated microenvironment 16, 17, conferring specific metabolic vulnerabilities 18-20 and shaping a unique tumor immune microenvironment (TIME) 16, 21. The gene discussed is NFE2L2; the disease is cancer.